This research study is being done because there is a need for systemic therapies for moderately severe plaque-type psoriasis that are both effective and have minimal side effects.

The purpose of this study is to examine the use of a new investigational medication for the treatment of moderate plaque-type psoriasis. The study medication is rimegepant, an orally administered small molecule competitive inhibitor of the calcitonin gene-related peptide (CGRP) receptor. This medication, rimegepant, has been approved by the FDA under the trade name Nurtec™ODT for the treatment of acute migraine. However, rimegepant has not been studied in the treatment of moderate plaque-type psoriasis and is investigational for this indication.

Participation in this study will last approximately 20 weeks (approximately 5 months) and will include approximately 12 study visits. At the end of the study, enrolled subjects will have the opportunity to participate in a 12 week open-label extension trial. 

Eligible participants will receive compensation for travel and inconvenience related to this study. Participants will receive a stipend of $50 for each completed study visit and will be offered an additional $100 for two optional skin biopsies, one at the start and end of the study.  Participants can receive a stipend of up to $1,000 for their completion of all 12 study visits and procedures.